Most other receptor tyrosine kinases employ the same signaling pathways and therefore the same mechanism is likely to apply to trastuzumab resistant breast cancer or gefitinib or erlotinib resistant NSCLC [21]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.